Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Free Cash Flow: 2020-2024

Historic Free Cash Flow for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to -$34.6 million.

  • SAB Biotherapeutics' Free Cash Flow fell 104.15% to -$13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.6 million, marking a year-over-year increase of 2.52%. This contributed to the annual value of -$34.6 million for FY2024, which is 36.79% down from last year.
  • SAB Biotherapeutics' Free Cash Flow amounted to -$34.6 million in FY2024, which was down 36.79% from -$25.3 million recorded in FY2023.
  • In the past 5 years, SAB Biotherapeutics' Free Cash Flow registered a high of -$2.7 million during FY2020, and its lowest value of -$34.6 million during FY2024.
  • Over the past 3 years, SAB Biotherapeutics' median Free Cash Flow value was -$25.6 million (recorded in 2022), while the average stood at -$28.5 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first slumped by 228.46% in 2021, then climbed by 1.21% in 2023.
  • Yearly analysis of 5 years shows SAB Biotherapeutics' Free Cash Flow stood at -$2.7 million in 2020, then plummeted by 228.46% to -$9.0 million in 2021, then crashed by 186.11% to -$25.6 million in 2022, then grew by 1.21% to -$25.3 million in 2023, then crashed by 36.79% to -$34.6 million in 2024.